Justin Steinkamp
Internal Medicine · Saint Charles, MONPI 1700351822
Payments from drug & device makers
Across 1,418 payments — averaging $98.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$64K
- Amgen$48K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Bayer$3K
- GSK$2K
- AstraZeneca$2K
- plus $18K from 49 others
What the payments were for
- Consulting fees$1,0821%
- Speaking & faculty fees$92,60067%
- Travel & lodging$9,7467%
- Food & beverage$35,67026%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$139,127 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 309 | $345,084 |
| MounjaroTirzepatide | 217 | $265,988 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 162 | $130,667 |
| Repatha SureclickEvolocumab | 140 | $121,823 |
| VraylarCariprazine Hcl | 68 | $120,251 |
| JardianceEmpagliflozin | 118 | $116,236 |
| FarxigaDapagliflozin Propanediol | 111 | $106,616 |
| EliquisApixaban | 86 | $81,296 |
| EntrestoSacubitril/Valsartan | 57 | $66,691 |
| RexultiBrexpiprazole | 30 | $53,537 |
| KerendiaFinerenone | 44 | $46,688 |
| CaplytaLumateperone Tosylate | 19 | $41,527 |
| UbrelvyUbrogepant | 30 | $37,883 |
| Nurtec OdtRimegepant Sulfate | 30 | $36,503 |
| QuliptaAtogepant | 28 | $32,302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,604 | $345,084309 claims |
| Lilly USA, LLCMounjaro | $1,228 | $265,988217 claims |
| AbbVieVraylar, Ubrelvy, Qulipta, Linzess | $63,718 | $215,599159 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $2,311 | $164,355219 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $389 | $129,958140 claims |
| PfizerEliquis, Nurtec Odt | $918 | $117,800116 claims |
| AstraZenecaFarxiga, Symbicort | $2,092 | $113,169134 claims |
| NovartisEntresto | $1,163 | $66,69157 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,058 | $53,53730 claims |
| BayerKerendia | $2,566 | $46,68844 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,954 | $41,52719 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $71 | $30,85927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Charles
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.